Earnings ·
Reports $269M Q3 WAKIX revenue, announces Peter Anastasiou to succeed Jeffrey Dayno as CEO
HRMYHarmony Biosciences Holdings, Inc.
Harmony Biosciences reported third-quarter 2026 net product revenue of $268.9 million for its narcolepsy treatment WAKIX, driven by 400 net patient adds and bringing the average patient count to 9,350. The company reiterated full-year guidance of $1.0 billion to $1.04 billion in WAKIX net revenue. Additionally, Peter Anastasiou will succeed Jeffrey Dayno as President and Chief Executive Officer effective January 1, 2027. The filing also disclosed preliminary positive data from a multiple-ascending dose study for the investigational orexin agonist BP-205. Harmony Biosciences develops and commercializes innovative medicines for rare and broad central nervous system disorders.